(2) Explain the rationale for metformin being the preferred initial pharmacologic agent for the treatment of type 2 diabetes
(T2DM) in terms of cardiovascular comorbid conditions, hypoglycemia risk, impact on weight, cost and risk for side
effects, etc. (3 points)